Imunon, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Imunon, Inc. (IMNN) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.19% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-08-11
- Imunon, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-03-31 was 4.19%.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-03-31 was 4.31%, a 27.14% increase year-over-year.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-03-31 was 3.39%, a 94.83% increase year-over-year.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2022-03-31 was 1.74%.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2015 was 0.78%, a 0.00% change from fiscal 2014.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2014 was 0.78%, a 0.00% change from fiscal 2013.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2013 was 0.78%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 4.19% 10-Q · filed 2026-08-11 | ||||
| 2026-03-31 | 4.19% 10-Q · filed 2026-05-12 | ||||
| 2024-06-30 | 4.31% 10-Q · filed 2025-08-05 | ||||
| 2024-03-31 | 4.31% 10-Q · filed 2025-05-12 | ||||
| 2023-09-30 | 3.72% 10-Q · filed 2024-11-07 | ||||
| 2023-06-30 | 3.72% 10-Q · filed 2024-08-14 | ||||
| 2023-03-31 | 3.39% 10-Q · filed 2024-05-13 | ||||
| 2022-06-30 | 1.74% 10-Q · filed 2023-08-10 | ||||
| 2022-03-31 | 1.74% 10-Q · filed 2023-05-11 | ||||
| 2020-03-31 | 1.33% 10-Q · filed 2021-05-14 | ||||
| 2019-03-31 | 2.65% 10-Q · filed 2020-05-15 | ||||
| 2018-06-30 | 3.08% 10-Q · filed 2018-08-14 | ||||
| 2018-03-31 | 2.82% 10-Q · filed 2019-05-15 | ||||
| 2017-09-30 | 2.21% 10-Q · filed 2018-11-14 | ||||
| 2017-06-30 | 2.21% 10-Q · filed 2018-08-14 | ||||
| 2016-06-30 | 1.87% 10-Q · filed 2016-08-15 | ||||
| 2015-12-31 | 0.78% 10-K · filed 2016-03-30 | ||||
| 2014-12-31 | 0.78% 10-K · filed 2015-03-12 | ||||
| 2014-03-31 | 2.75% 10-Q · filed 2014-05-08 | ||||
| 2013-12-31 | 0.78% 10-K · filed 2014-03-13 | ||||
| 2013-09-30 | 0.78% 10-Q · filed 2013-11-12 | ||||
| 2013-06-30 | 0.78% 10-Q · filed 2013-08-08 | ||||
| 2013-03-31 | 0.85% 10-Q · filed 2014-05-08 | 0.78% 10-Q · filed 2013-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |